Cell Genesys, Inc.
500 Forbes Boulevard
South San Francisco
California
94080
U.S.A.
Phone:
650-266-3000
Fax:
650-266-3010
|
Cell Genesys (Nasdaq: CEGE) is focused on the development and commercialization of novel biological therapies for patients with cancer. The company's lead product platform is GVAX® immunotherapy for cancer. Ongoing clinical trials of GVAX cancer immunotherapies include two Phase 3 trials of GVAX immunotherapy for prostate cancer, which is being developed in partnership with Takeda Pharmaceutical Company Limited. Other programs include GVAX immunotherapy for leukemia and GVAX immunotherapy for pancreatic cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, California, and has manufacturing operations in Hayward, California.
Management Team:
Stephen A. Sherwin, M.D.
Chairman and Chief Executive Officer
Sharon E. Tetlow
Senior Vice President and Chief Financial Officer
Robert J. Dow
Chief Medical Officer
Carol C. Grundfest
Senior Vice President, Regulatory Affairs and Portfolio Management
Kristen M. Hege, M.D.
Vice President, Clinical Research
Christine McKinley
Senior Vice President, Human Resources
Michael W. Ramsay
Senior Vice President, Operations
Robert H. Tidwell
Senior Vice President, Corporate Development
Peter K. Working, Ph.D.
Senior Vice President, Research and Development
Email:
ir@cellgenesys.com
Ownership:
Web Site:
Cell Genesys, Inc.
Employees:
335
Symbol: CEGE
|
|
|
Company News |
BioSante Pharmaceuticals, Inc. (BPAX) and Cell Genesys, Inc. (CEGE) Announce Completion of Merger
10/14/2009 11:35:06 AM
More...
|
BioSante Pharmaceuticals, Inc. (BPAX) And Cell Genesys, Inc. (CEGE) Announce Approval of Merger by BioSante Stockholders and Adjournment of Cell Genesys Stockholders Meeting Until October 14, 2009
10/1/2009 10:44:21 AM
More...
|
BioSante Pharmaceuticals, Inc. (BPAX) and Cell Genesys, Inc. (CEGE) Announce Final Exchange Ratio for Merger
9/23/2009 8:56:01 AM
More...
|
RiskMetrics – ISS Governance Services Recommends Stockholders Vote “FOR” BioSante Pharmaceuticals, Inc. (BPAX) and Cell Genesys, Inc. (CEGE) Merger
9/17/2009 9:21:15 AM
More...
|
BioSante Pharmaceuticals, Inc. (BPAX) and Cell Genesys, Inc. (CEGE) Announce September 30, 2009 Special Stockholders Meetings to Approve Merger
9/3/2009 9:55:36 AM
More...
|
Cell Genesys, Inc. (CEGE) Announces Second Quarter 2009 Financial Results
8/5/2009 9:49:15 AM
More...
|
BioSante Pharmaceuticals, Inc. (BPAX) to Buy Cell Genesys, Inc. (CEGE) for $38 Million
6/30/2009 7:54:27 AM
More...
|
Cell Genesys, Inc. (CEGE) Announces Tender Offer Results While Continuing to Pursue Strategic Alternatives
6/23/2009 9:42:37 AM
More...
|
Cell Genesys, Inc. (CEGE) Announces Tender Offer Results While Continuing to Pursue Strategic Alternatives; Company’s Staff Down to 9
6/23/2009 7:33:52 AM
More...
|
Cell Genesys, Inc. (CEGE) Commences Exchange Offer for $68.3 million Convertible Notes
5/26/2009 9:17:07 AM
More...
|
|
|
|